跳至主要内容
临床试验/NCT02300870
NCT02300870终止不适用

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
10
试验地点
1
主要终点
Global and regional microvascular myocardial perfusion

研究概览

简要总结

The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the efficacy of this technique in generating data which allow for the assessment of short and long term outcomes.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All adult subjects (ages 18 to 75) who have undergone heart transplant at Brigham and Women's Hospital

排除标准

  • hemodynamic instability (e.g., systolic blood pressure < 90 mmHg)
  • atrial fibrillation with rapid ventricular response (e.g., heart rate > 120 bpm)
  • premature atrial or ventricular complexes of a frequency that will not allow adequate echocardiographic assessment
  • poor acoustic windows
  • inability to provide informed consent
  • any contraindication listed in the Optison package insert (i.e., history of an allergic reaction)

研究组 & 干预措施

Heart Transplant Rejection

Patients presenting with acute cellular rejection

干预措施: Optison (Drug)

Heart Transplant Control

Patients presenting for routine office visit

干预措施: Optison (Drug)

结局指标

主要结局

Global and regional microvascular myocardial perfusion

时间窗: Baseline

Myocardial blood flow (dB/s)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Givertz, MD

Medical Director, Heart Transplant and Mechanical Circulatory Support

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验